Angiotensin-II receptor antagonist losartan reduces micro albuminuria in hypertensive renal transplant recipients

Simple item page
dc.contributor.buuauthorAlparslan, Ersoy
dc.contributor.buuauthorDilek, Kamil
dc.contributor.buuauthorUsta, Mehmet
dc.contributor.buuauthorYavuz, Mahmut
dc.contributor.buuauthorGüllülü, Mustafa
dc.contributor.buuauthorYurtkuran, Mustafa Abbas
dc.contributor.buuauthorOktay, Burçin
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid56005080200tr_TR
dc.contributor.scopusid7005030712tr_TR
dc.contributor.scopusid7006244754tr_TR
dc.contributor.scopusid6602684544tr_TR
dc.contributor.scopusid6602172127tr_TR
dc.contributor.scopusid7003389525tr_TR
dc.date.accessioned2022-03-14T08:22:38Z
dc.date.available2022-03-14T08:22:38Z
dc.date.issued2002-06
dc.description.abstractIn recent years, it has been demonstrated that losartan lowers macroproteinuria in diabetic or non-diabetic renal transplant recipients (RTx) similar to angiotensin converting enzyme (ACE) inhibitors. Microalbuminuria (MAU) may reflect subclinical hyperfiltration damage of the glomerulus. It could be a marker of kidney dysfunction in renal transplantation. The aim of the study was to assess the efficacy of losartan in hypertensive RTx with MAU. This study was conducted in 17 (M/F: 4/13) stable RTx. No change was made in the medical treatment of the patients. All cases received 50 mg/day losartan therapy for 12 wk. Renal functions and MAU were determined 12 and 6 wk and just before the treatment as well as sixth and twelfth week of the treatment in all patients. Losartan satisfactorily lowered systemic blood pressure. A significant reduction in MAU was observed from 103 +/- 53 mug/min at the beginning to 59 +/- 25 mug/min in the sixth week and 47 +/- 24 mug/min in the twelfth week (p = 0.0007 and 0.0005, respectively). From the sixth week of the treatment, the therapy significantly decreased hemoglobin, hematocrit and erythrocyte levels but did not change mean leukocyte and platelet counts, urea, creatinine levels and creatinine clearances. No serious side-effect was observed,during the study. In conclusion, we found that losartan decreased MAU in hypertensive RTx. For that reason, it might be considered as the first choise antihypertensive agent for the renoprotection in selected patients.en_US
dc.identifier.citationErsoy, A. vd. (2002). "Angiotensin-II receptor antagonist losartan reduces micro albuminuria in hypertensive renal transplant recipients". Clinical Transplantation, 16(3), 202-205.en_US
dc.identifier.endpage205tr_TR
dc.identifier.issn0902-0063
dc.identifier.issue3tr_TR
dc.identifier.pubmed12010144tr_TR
dc.identifier.scopus2-s2.0-0036308902tr_TR
dc.identifier.startpage202tr_TR
dc.identifier.urihttps://doi.org/10.1034/j.1399-0012.2002.01127.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1034/j.1399-0012.2002.01127.x
dc.identifier.urihttp://hdl.handle.net/11452/24979
dc.identifier.volume16tr_TR
dc.identifier.wos000176236300009tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.journalClinical Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenoprotectionen_US
dc.subjectAngiotensin II receptor blockadeen_US
dc.subjectHypertensionen_US
dc.subjectKidney transplantationen_US
dc.subjectLosartanen_US
dc.subjectMicroalbuminuriaen_US
dc.subjectDiseaseen_US
dc.subjectCyclosporineen_US
dc.subjectNephropathyen_US
dc.subjectProteinen_US
dc.subjectFailureen_US
dc.subject.emtreeAlbuminen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeRenovascular hypertensionen_US
dc.subject.emtreeBlood pressureen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeThrombocyte counten_US
dc.subject.emtreeDisease markeren_US
dc.subject.emtreeCoughingen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeDrug choiceen_US
dc.subject.emtreeImmunosuppressive treatmenten_US
dc.subject.emtreeCreatinine clearanceen_US
dc.subject.emtreeDiabetes mellitus dose responseen_US
dc.subject.emtreeDrug blood levelen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeErythrocyte levelen_US
dc.subject.emtreeHematocriten_US
dc.subject.emtreeGlomerulonephritisen_US
dc.subject.emtreeGlomerulus filtrationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHemoglobin determinationen_US
dc.subject.emtreeHypotensionen_US
dc.subject.emtreeKidney dysfunctionen_US
dc.subject.emtreeKidney function testen_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMicroalbuminuriaen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePoteinuriaen_US
dc.subject.emtreeRecipienten_US
dc.subject.emtreeAlbuminen_US
dc.subject.emtreeAngiotensin 2 receptor antagonisten_US
dc.subject.emtreeAntihypertensive agenten_US
dc.subject.emtreeAzathioprineen_US
dc.subject.emtreeCalciumen_US
dc.subject.emtreeCalcium channel blocking agenten_US
dc.subject.emtreeChlorideen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeCyclosporin Aen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeDiuretic agenten_US
dc.subject.emtreeHemoglobinen_US
dc.subject.emtreeImmunosuppressive agenten_US
dc.subject.emtreeLosartane
dc.subject.emtreePhosphorusen_US
dc.subject.emtreePotassiume
dc.subject.emtreePrednisoloneen_US
dc.subject.emtreeSodiumen_US
dc.subject.emtreeUreaen_US
dc.subject.emtreeUric aciden_US
dc.subject.meshAdulten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAngiotensin IIen_US
dc.subject.meshAlbuminuriaen_US
dc.subject.meshAntihypertensive agentsen_US
dc.subject.meshBlood pressureen_US
dc.subject.meshLosartanen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertensionen_US
dc.subject.meshKidney transplantationen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.scopusKidney Transplantation; Transplant Recipients; Ambulatory Blood Pressure Monitoringen_US
dc.subject.wosSurgeryen_US
dc.subject.wosTransplantationen_US
dc.titleAngiotensin-II receptor antagonist losartan reduces micro albuminuria in hypertensive renal transplant recipientsen_US
dc.typeArticle
dc.wos.quartileQ2 (Surgery)en_US
dc.wos.quartileQ3 (Transplantation)en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ersoy_vd_2002.pdf
Size:
73.29 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus